Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ed as unequivocal relief or the presence of one or two consecutive 15 minute assessments consistent with improvement immediately prior to discharge, occurred in 73 percent of attacks within one hour, and 95 percent within four hours;
  • 65 percent of laryngeal attacks achieved unequivocal relief or at least one report consistent with improvement immediately prior to discharge within one hour, and 90 percent within four hours;
  • Of the 84 laryngeal attacks, none required intubation after the receipt of Cinryze;
  • Responses to Cinryze in subjects with more than one attack did not diminish with subsequent repeated administration;
  • Infusion site pain, joint swelling, rash, and sinusitis were reported as treatment-emergent Cinryze-related adverse events.  

  • In a poster entitled, "Open-Label Use of Nanofiltered C1 Esterase Inhibitor (Human) (nf-C1 INH) for Treatment of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects,' Dr. Timothy Craig, M.D. of the Hershey Medical Center in Harrisburg, PA, presented open label experience with Cinryze in treating 121 HAE attacks in 22 pediatric patients with HAE. Data from this study included the following:

    • The overall median time to beginning of relief of all attacks was 15 minutes;
    • Overall response rates within 4 hours were 89 to 97 percent for unequivocal relief and clinical relief, respectively;
    • No subjects with a laryngeal attack required intubation;
    • In subjects who were treated for multiple attacks, repeated therapy with Cinryze did not diminish the response to treatment;
    • Of the 121 acute attacks treated with Cinryze, 88 attacks were treated with one dose of Cinryze; 33 attacks required two doses;
    • There were no serious adverse events, and no adverse events were considered related to Cinryze.  No subject discontinued study drug due to an adverse event;  
    • There was no evid
      '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
    2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
    3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
    4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
    5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
    6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
    7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
    8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
    10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
    11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2015)... May 27, 2015 PharmaPoint: Type 1 Diabetes - ... Type 1 diabetes (T1D) is an autoimmune disease that ... that the body can no longer produce insulin. Over the ... at present, no other treatment can be offered to a ... insulin analogs with different times of action - long-acting as ...
    (Date:5/27/2015)...  Precision Advisors ( www.precisionadvisors.com ), a Precision for ... Trends Study of 145 managed care executives. The study ... of big data and predictive analytics, but are not ... Health Information Technology for Economic and Clinical Health Act ... of electronic medical records (EMRs) by 2014. While a ...
    (Date:5/27/2015)... May 27, 2015  LumiThera Inc., a developmental ... (PBM) treatment for ocular disorders and disease, announced ... Washington State Life Sciences Discovery Fund (LSDF) ... of the LSDF matching grants worth $500,000 to ... subjects with dry age-related macular degeneration (AMD). ...
    Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
    ... New Somatropin Formulation Demonstrate Advantages ... Over Existing Once-Daily ... Nottingham, UK-based speciality pharmaceuticals,company, today announced that the successful ... the synthetic human growth,hormone (hGH) somatropin. Trials demonstrated therapeutic ...
    ... released by The Philadelphia AIDS Consortium:, WHO: ... its network of eleven (11) community-based organization,sites located ... 30 AmeriCorps ACTS members working throughout New,Jersey, Delaware ... 9 a.m. until Noon; Media Focused,Event 10:30 - ...
    Cached Medicine Technology:Critical Pharmaceuticals Enter Sustained Release hGH Arena 2Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures 2
    (Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
    (Date:5/27/2015)... Arizona (PRWEB) May 27, 2015 Continuing ... mission of healthier patients in the community, SmartPractice® ... Center (formerly John C. Lincoln). SmartPractice Vice President of ... Michelle Shaw presented a $25,000 check to Paulla Miller, ... HonorHealth’s Breast Health & Research Center on April 30. ...
    (Date:5/27/2015)... May 27, 2015 Dr. Omar Ibrahimi, ... in Stamford, CT has been selected as part of ... physicians nationwide (and the only physician in Connecticut) to ... allows for the removal of submental fat (double chin). ... recovery time, no surgery and minimal risks. Dr. Ibrahimi ...
    (Date:5/27/2015)... CURE® Magazine and the Bladder ... advance research, provide information and support, and raise awareness ... fifth most common type of cancer, which begins when ... out of control. , “CURE Magazine provides guidance ... the cancer experience through digital and print publications, live ...
    (Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
    Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3
    ... Million in Compensation and Benefits, MINNEAPOLIS, Dec. 6 ... William McGuire, today agreed to,terms with the UnitedHealth Special ... than $420 million in stock options and other,compensation to ... during,his tenure as CEO of the company, in addition ...
    ... against colorectal, prostate and oral tumors , , THURSDAY, ... from black raspberries, a fruit beverage and old-fashioned ... to treat or prevent different types of cancer, ... not been considered good treatments for chronic illness, ...
    ... Inc. (NYSE: WPI ), a leading ... reached a settlement with Novartis,Pharmaceuticals Corporation, Novartis ... and Proterra AG (collectively,"Novartis") on outstanding patent ... (rivastigmine tartrate) capsules., Under the terms ...
    ... (Nasdaq: NBIX ) announced today that the ... Veralliance Properties for its real estate,assets. Total consideration ... Concurrently with the closing of the transaction, Neurocrine,leased ... term, with renewal,options. Neurocrine also has certain options ...
    ... EXEL ) announced today that that it will hold ... of Hematology,48th Annual Meeting from 8:00 p.m. to 9:00 p.m. ... webcast and may be accessed in the Event Calendar,page under ... -- Michael Morrissey, PhD, President of Research & Development ...
    ... University of Pennsylvania School of Medicine and other ... care providers can better their chances of identifying ... the way they ask patients questions., In a ... Internal Medicine, researchers found a number of communication ...
    Cached Medicine News:Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 2Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 3Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 2Health News:Green Tea, Fruit Extracts Touted as Potential Cancer Fighters 3Health News:Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation 2Health News:Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets 2Health News:Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting 2Health News:Finding the right words: Provider-patient discussions can help domestic violence victims speak up 2
    Midstream Catch Kits...
    ... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
    ... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
    ... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
    Medicine Products: